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RÉSUMÉ
Objectif: L’objectif de cette étude est de déterminer les facteurs prédictifs de la
progression de l’hypertension gestationnelle (HG) en prééclampsie (PE), parmi les
femmes qui initialement présentaient une HG, en créant un modèle qui puisse prédire
cette progression. Protocole expérimental: C’est une étude de cohorte rétrospective de
280 patientes présentant initialement une hypertension gestatioimelle; 189 patientes ont
évolué vers une PE, 91 sont restées avec une hypertension gestationnelle jusqu’à
l’accouchement. Les données ont été comparées par une analyse du Chi deux, un test
exact de fisher, une analyse de la variance, une analyse de régression logistique univariée
et multivariée, lorsque applicable. Résultats: Trois facteurs prédictifs significatifs (un
antécédent de PE, un taux d’acide urique et l’âge gestatiormel lors de la détection de Ï’HG)
étaient associés à la progression de l’HG en PE dans une analyse de régression logistique
multivariée. Un modèle de prédiction multivarié a été développé, avec une sensibilité =
81.5%, spécificité = 84.6%, valeur prédictive positive = 91.7%, et valeur prédictive
négative = 68.8%. Conclusions: Une hypertension gestatiormelle précoce, une histoire de
prééclampsie antérieure et le taux d’acide urique sont des variables associés à la
progression de l’hypertension gestationnelle vers la prééclampsie. Notre modèle utilise de
simples facteurs prédictifs disponibles lors des soins de routine périnataux; qui ont
raisonnablement de bons paramètres de validité pour prévoir la probabilité de progression
de l’hypertension gestationnelle en prééclampsie; qui peuvent fournir un outil simple
utile dans la gestion du risque de patientes présentant une hypertension gestationnelle.
Mots clés: Sensibilité, Spécificité, Modèle de prédiction multivarié, Age gestationnel,
Antécédent de prééclampsie, Acide urique.
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ABSTRACT
Objective: Littie is known on why some women with gestational hypertension (GH)
progress to preeclampsia (PE) while others do not. The objective of this study was to
throw light on the predictors of progression to PE, among women who initially present
with GH and to create a model which could predict this progression. Research design:
This was a retrospective cohort study of 280 patients with an initial presentation of GH;
189 patients progressed to PE, and 91 patients remained as GH until delivery. Data were
compared by Chi square or fisher exact tests, analysis of variance and by univariable and
multivariable logistic regression analysis where applicable. Resuits: In the multivariable
logistic regression analysis, three significant predictors were associated with progression
from GH to PE: prior history ofPE, une acid level and gestational age at GH presentation.
A multivaniable prediction model was developed, with sensitivity 81.5%, specificity
84.6%, positive predictive value = 9 1.7%, and negative predictive = 68.8%. Conclusions:
Early onset GH, prior history of PE and uric acid level are variables associated with the
progression from GH to PE. Our model uses simple predictors available in routine
perinatal care and lias reasonably good validity parameters for predicting the probability
of progression from GH to PE, which may provide a useful simple tool in the risk
management of patients with gestational hypertension.
Key words: Sensitivity, Specificity, Multivariable predictive model, Gestational age,
Prior preeclampsia history, Unie acid.
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11. Literature review
1.1. Introduction
Hypertensive disorders in pregnancy remain a major cause of maternai, fetai and
neonatai morbidity and mortality in worldwide countries. An estirnated one-third of ail
maternai deaths in Canada are caused by hypertensive disorders, a trend that has changed
littie since the eariy 1970s.’ Pregnant women with hypertension, either newly diagnosed
or pre-existing, remain at risk for severe complications such as abruptio placenta,
cerebrovascular disorders, end-organ failure and disserninated intravascular coaguiation.2
As well, the fetus is at risk for intrauterine growth restriction (RJGR), prematurity and
intrauterine death.2589
Despite recent advances in our understanding of the pathophysioiogy and treatment
of hypertensive disorders in pregnancy, confusion abounds in the iiterature regarding the
definitions and classifications of such disorders.
Hypertensive disorders in pregnancy affect about 6 to 10 % of ail pregnancies and
remain a major cause of maternai and neonatal mortality and morbidity worldwide. In
deveioped countries, preeclampsia primarily affects fetal and neonatal weil-being through
intrauterine growth restriction (RJGR), preterm birth and low birth weight. A significant
component of neonatal morbidity is attributed to preterm deiivery undertaken to prevent
further deterioration in the fetus and mother.’° In fact, about 15% of ail preterm births are
indicated deliveries for preeciampsia.11 Preterm birth has been associated with increased
risks of neonatal mortality and long-term neurological disabiiity. Preeclampsia also
increases the risk of intrauterine growth restriction (IUGR). Growth restricted babies not
only have an increased risk of acute problems but, more alarmingly, IUGR may confer a
iong-term burden in future cardiovascular risk.12’3
from a public health perspective, it is of concem that the rate of preeclampsia has
2increased by 40% between 1990 and 1999 in a study report,’4 probably the resuit ofa rise
in the number of older mothers and multiple births, conditions that predispose to
preeclampsia.
1.2. Classification of Hypertensive Disorders in Pregnancy
Classification of hypertensive disorders in pregnancy has varied in the past and led
to some confusion in both the clinical management and research efforts toward the
etiology of these disorders. The most recent classification recommended by the National
High Blood Pressure Education Program5 is as follows.
• Preeclampsia / Eclampsia;
• Gestational hypertension;
• Chronic hypertension;
• Preeclampsia superimposed on chronic hypertension.
These categories identify disorders with different epidemiological characteristics,
pathophysiology, and risks for mother and baby. Previous terminology such as
Pregnancy-induced hypertension lias been gradually abandoned.16 These categories are
summarized below.
1.2.1. Preectainpsia
Preeclampsia is defined as the de novo appearance of hypertension (systolic blood
pressure of 140 mmHg or diastolic blood pressure of 90 mmHg), accompanied by
new-onset proteinuria, defined as 300 mg per 24 hours; occurring after 20 weeks of
gestational age. Previous definitions included edema, but this sign is non-specific and is
observed in many normotensive pregnant women. Thus, edema is no longer considered to
be part of the diagnostic criteria for preeclampsia. Likewise, previous criteria in which a
rise of 30 mmHg in systolic pressure andlor 15 mmHg in diastolic pressure were
considered diagnostic have been eliminated as too non-specific, identifying up to 25% of
3pregnant women.17 In addition, probably because of this lack of specificity, it is very
difficuit to demonstrate an excess ofmorbidity in these women.17 As proteinuria may be a
late manifestation of preeclampsia, it should be suspected when de novo high blood
pressure is accompanied by headache, abdominal pain, or abnormal laboratory tests,
specifically low platelet count and abnormal liver enzymes. It is prudent to treat such
patients as if they may develop preeclampsia later.
Eclampsia occurs when preeclampsia progresses to a life-threatening convulsive
phase. Such convulsions usually occur afler mid-pregnancy or during delivery, but as
many as one third of eclamptic convulsions occur during the first 48 hours afler delivery.
In fact, in the era of adequate blood pressure control, preeclampsia-associated
mortality is most commonly due to either hepatic necrosis or aduit respiratory distress
syndrome, both ofwhich are the consequences of systemic inflammation)8
1.2.2. Gestationat hypertension
Gestational hypertension is defined as increased blood pressure (> 140 mmHg
systolic or> 90 mmHg diastolic pressure) first diagnosed afler 20 weeks’ gestation and
flot accompanied by proteinuria. Gestational hypertension may later satisfy diagnostic
criteria for preeclampsia if accompanied by proteinuria ( 300 mg/24 hrs) during
pregnancy. However, in many cases proteinuria neyer occurs, the course is relatively
benign, and the blood pressure normalizes afler delivery.
1.2.3. Chronic hypertension
Chronic hypertension refers to an elevated blood pressure in the mother that
predated the pregnancy. It can be diagnosed when elevated blood pressure is detected
before the 2Oth week of gestation and can also be diagnosed retrospectively when
hypertension fails to normalize within 6 weeks of delivery. Blood pressure generally falis
in the first and second trimesters; therefore women with high blood pressure before the
42Oth week of gestation are assumed to have pre-existing hypertension. Chronic
hypertension may also not have been recognized before the pregnancy. The absence of
clinical data to guide medical treatment strategies is particularly disconcerting because
women with chronic hypertension are at increased risk of superimposed preeclampsia
(15-25%), preterm delivery, fetal growth restriction or demise, abruptio placenta,
congestive heart failure, and acute renal failure. There is no evidence that treatment of
chronic hypertension reduces the probability of developing preeclampsia and its
complications in this high risk group.
1.2.4. Preectainpsia superimposed 011 chronic hypertension
The outcome for mothers and infants with preeclampsia superimposed on existing
hypertension is worse than with de novo preeclampsia.” Women with chronic
hypertension have a 15 to 25% risk of developing preeclampsia during pregnancy. It is
sometimes difficuit to establish a differential diagnosis between the deterioration of
chronic hypertension and the onset ofpreeclampsia. A rapid increase in proteinuria or the
development of laboratory signs suggesting organ damage, such as elevated liver
enzymes or thrombocytopenia, can help in diagnosing preeclampsia.
AIl women with raised blood pressure must be carefully monitored for the
associated features of preeclampsia.
1.3. Preeclampsia: Current Concepts
1.3.1. History
Eclarnpsia was described by Celsus in 100 AD as seizures during pregnancy that
abated with delivery.19 For the ensuing 2000 years, eclampsia was considered to be a
pregnancy-specific seizure disorder. It was flot until the rnid-1800s that the similarity of
the edematous eclamptic woman and the dropsic patient with Bright’s disease (acute
glomerulonephritis) stimulated clinicians to determine whether women with eclampsia,
5like individuals with Bright’s disease, had protein in their urine. Protein was indeed
present in the urine of eclamptic women. Furthermore, it was recognized that the
proteinuria usually antedated the seizures. In another 50 years, it was possible to measure
blood pressure noninvasively. Again, the association behveen increased blood pressure
and eclampsia was recognized, as was the fact that the hypertension also antedated the
seizures)9 It soon became evident that hypertension and proteinuria during pregnancy,
even without seizures, identified a woman with the potential for a rapidly progressive
life-threatening disorder and a fetus at increased risk for stillbirth. These hvo findings of
renal dysfttnction and hypertension guided research for more than 80 years. It was not
until about 10 years ago that investigators began focusing on the pathophysiology and
multiple systemic manifestations of preeclampsia.
1.3.2. Epidemiological characteristics
The epidemiology of preeclampsia is complicated by differences in definitions and
inaccuracy of diagnosis. A single blood-pressure reading of 140/90 mm Hg or above is
not uncommon in pregnancy and was reported in nearly 40% of pregnant women in one
study.2° Such a finding carnes little risk to the mother or fetus. Persistent hypertension is
diagnosed if an abnormal reading is found on two occasions at least 4h apart.21 The type
of hypertension can be further defined on the basis of other clinical signs, particularly
proteinuria and abnormalities of coagulation.22
Differences in diagnostic criteria and poor record keeping make it virtually
impossible to compare the frequency of preeclampsia in different populations from
routinely collected data. It is clear that death rates from the disorder are higher in
developing countries; however, this need not indicate increased disease ftequency. Death
from preeclampsia is largely preventable by appropriate care. Death rates are primarily a
marker of quality of care rather than disease frequency. There is a suggestion of an
increased risk ofpreeclampsia in black women. Although the disorder appears to be more
common in young women, when the “first pregnancy effect” is controlled for,
6preecÏampsia is actually more frequent in older women.23
Preeclampsia is twice as common in primigravid women than in women having
second or later pregnancies.24 However, with a change of partner, the risk in a
multiparous woman increases; this effect suggests that primipatemity is important. Some
men seem to have an increased risk of fathering a preeclamptic pregnancy.25 Women who
become pregnant with donor eggs have a higher frequency of preecÏampsia than women
pregnant with their own eggs;26 this finding suggests that any new fetal factors are
important, not necessarily those ofpatemal origin.
1.3.3. Pathophysïology
Preeclampsia is the resuit of an initial piacental trigger, and a maternai systemic
reaction that produces the clinical signs and symptoms of the disorder.27 In 2005,
Redman28 reviewed some new and interesting advances in understanding preeclampsia,
include the conception of placental preecl ampsia and ni atemal preeclampsia. Placental
preeclarnpsia progress w ith preclinical stage, which characteristics as poor piacentation,
inhibited trophoblast invasion and poorly rernodeled arteries. Whereas maternai
preeclarnpsia lias the characteristic as more an abnonnai maternai response problem than
an abnomial pregnancy, such as maternai arteriai disease, hypertension, obesity or
diabetes.
1.3.3.1. Placenta! trigger
Preeclampsia occurs oniy in the presence of a placenta. Although it can be
associated with a failure of the normal invasion of trophobiast celis, leading to
maladaptation of maternai spiral arterioles,29 it can also be associated with
hyperpiacentation disorders such as diabetes, hydatidiform mole, and multiple pregnancy.
The maternal arterioles are the source of blood supply to the fetus, and maladaptation of
these vessels can interfere with normai villous deveiopment. In some cases, compensation
7can occur, but, in others, poor villous deveiopment resuits in placental insufficiency.3°
Secondary damage, such as fibrin deposition and thrombosis can then occur within the
placenta. These features are found in cases of piacental insufficiency, whether
preeclampsia is present or not.31 Not ail women with the potential placental trigger
deveïop preecÏampsia; therefore the maternaI response appears to be a decisive factor in
the development of systemic disease.
1.3.3.2. Maternai response
Aithough preeciampsia is said to be a vascular endothelial disorder,32 it is a
muitisystem disorder with various forms. This variation could be due to different vascular
beds being affected to varying degrees, but later research has shown that there is a strong
maternai inflammatory response.27 Aithough this response has been described in the
piacental bed,33 there is far broader immunological systemic activity.27 These changes
may explain many ofthe ciinical signs, inciuding the endothelial-celi dysfunction.
Because preeciampsia is diagnosed by the presence of hypertension and proteinuria,
the remaining systemic features can vary from mild cases with littie systemic
involvement, to multiorgan failure in severe cases. How extensiveiy the disease deveiops
depends on various modifying factors, which could be genetic or environmental in origin.
1.3.3.3. Hereditaiyfactors
The epidemioiogicai features ofpreeciampsia suggest a genetic basis for the disorder.
Preeclampsia is more common in daughters ofpreeclamptic women34 and in pregnancies
fathered by sons of preeciamptic women,35 suggesting the involvement of both maternai
and fetal genes in the syndrome.
Preeclarnpsia can be familial.36 However, various groups have studied the genetic
basis of this disorder and no consistent resuits have been obtained. A singie preeciampsia
gene is unlikeiy; there are probably severai modifier genes interacting with environrnental
$factors to determine whether an individuai woman may deveiop the disease.37 There have
been conflicting resuits for the genes that encode angiotensinogen, superoxide dismutase,
tumour necrosis factor a, methylenetetrahydrofolate reductase, factor V Leiden, and
endothelial nitric oxide synthase. These studies concentrated on maternai genetics and
ignored the potential paternal and fetal influences.25 The resuits of large muiticentre
studies with the use of modem chip tecimology for genorne scanning with multiple
microsatellite markers are awaited to clarify the role of genetics in the pathophysiology of
preeclampsia.37 In addition, genetic markers of the disease would be useful flot only in
identifying relevant molecules but also would facilitate longitudinal studies of
pathogenesis.
1.3.4. Subclassification of Preeclampsia
Preeclampsia / eclampsia is a maternai syndrome that probably arises through
multiple pathways. It varies from the usually evanescent disease of preeclampsia at term
to the severe disease most commonly developing remote from temi. There is some
evidence to support its subciassfication on the basis of gestational age at disease onset.
1.3.4.1. Preectampsia: Curreitt classification
Most recently, guidelines for the diagnosis and management of preeclampsia have
been produced by the Canadian Hypertension Society,2’ the US National High Blood
Pressure Education Program Working Group on High Blood Pressure in Pregnancy,38 and
the Australasian Society for the study of hypertension in Pregnancy (ASSHP),39 as well
as International Society for the Study of Hypertension in Pregnancy (ISSHP).4° Later in
2002, Pridjian G41 published an article, summarized preeclampsia classification as
follows:
1. Mild preeclampsia is defined as a blood pressure (BP) of 140 / 90 mm Hg or
higher with proteinuria of 0.3 to 5 g!day; the evidence of other organ dysfunction is
9flot present. The importance of making this diagnosis is related to the fact that
maternai and fetal surveillance are subsequently increased. New onset hypertension
in pregnancy or gestational hypertension should also be followed carefully because
10% of eclampsia occurs before significant proteinuria.42 Forerunners to the
diagnosis of mild preeclampsia include the sudden onset of weight gain or edema,
and an increase in blood pressure.
2. Severe preeclampsia is defined as a systolic blood pressure greater than or equal
to 160 mm Hg or a diastolic blood pressure greater than or equal to 110 mm Hg or if
hypertension is complicated by significant proteinuria (>=5 g/day), or by evidence of
end-organ damage. The following signs and symptoms, aithough variably present,
are associated with severe preeciarnpsia: headache, visual disturbances, confusion,
right upper quadrant or epigastric pain, impaired iiver function, proteinuria, oliguria,
pulmonary edema, microangiopathic hemolytic anemia, thrombocytopenia,
oligohydramnios, and fetal intrauterine growth restriction (IUGR).
Whiie dichotomizing preeclampsia in this way presumabiy differentiates women
with iower risk from those with higher risk for perinatal outcomes, the definition aiiows
no “shades ofgray”.
All classifications are predicated on the occurrence of hypertension, proteinuria and
other organ dysfunction, none of which is present in 10% of women within 1 week prior
to their first eclamptic seizure.43 Also, gestational age at presentation is flot a criterion for
diagnosis, severity, or subclassification.
1.3.4.2. Earty or tate-onsetpreectampsia
That gestational age has flot been accounted for in any of the current classification
systems is a major probiem. It is the most important clinical variable in predicting both
maternai and perinatal outcomes. Eariy-onset preeclampsia represents considerable
additionai maternai risk, as maternai mortaiity has been reported to be 20-fold higlier
10
when preeclampsia onset is less than 32 weeks’ gestation than when preeclampsia occurs
at terrn.44 In addition, data indicate that early onset preeclampsia may be a quaÏitatively
different disease. This is supported by observations that the pathophysiology of early
onset preeclampsia differs from late-onset disease, in terms of neutrophil function45 and
cytokine 1eve1s.457 Also, there is compelling epidemiologic evidence that early-onset
disease (defined as onset earlier than 28 weeks) is associated with a greater risk for
recurrence in later pregnancies,46 and an increased risk for later cardiovascular disease
and death.4953 Being delivered at less than 37 weeks’ gestation by a mother whose
pregnancy was complicated by preeclampsia increases the lifetime hazard for death from
cardiovascular disease by 7.1 (crude odds ratio)5’ to 8.152 fold. Furthermore, the
concurrence of intrauterine growth restriction, preeclampsia, and preterm birth (<37
weeks’ gestation) confers an adjusted hazard ratio for cardiovascular death of 16.151
compared with normotensive pregnancies of appropriately grown fetuses at term.
Von Dadelszen45 reported in 2002 that a greater than 50% chance of survival for a
fetus delivered of a woman with preeclampsia is attained when the gestational age at
delivery is 27 weeks’ and/or the birthweight 600 g. Also, Xiong et al54 reported that
early-onset preeclarnpsia, but not preeclampsia arising at term, is an important predictor
of intrauterine growth restriction (IIJGR). In fact, recent data suggest that IUGR is a
function of preeclampsia arising before 37 weeks’ gestation.54 Furthermore, there is an
increase in large babies among women with preeclampsia delivering after 37 weeks’
gestation.55
For these reasons, women with early-onset preeclampsia may provide the most
homogeneous data for differentiating the changes of preeclampsia from those of normal
pregnancy.
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1.3.5. MaternaI-Fetal Interactions in Preeclampsia
An important question which remains unanswered is “how does reduced placental
perfusion resuit in the maternai preeciampsia syndrome?” It is clear that reduced
perfusion aTone is flot sufficient to explain preeciampsia. Intrauterine growth restriction
may be the resuit of reduced placental perfusion. However, many women with a growth
restricted fetus do not develop preeclampsia, and a small percentage of preeclamptic
women have large fetuses. In addition, implantation defects including failure to remodel
blood vessels that suppiy the placenta (a characteristic of preeciampsia) are present in
pregnancies with fetai growth restriction56 and in one-third of pregnancies ending in
spontaneous preterm births.57 This has led some to postulate that reduced piacental
perfusion must interact with maternai factors to result in the maternai preeciampsia
syndrome. These factors are posited to be genetic, behavioral, or environrnental.
The fetal syndrome is manifested by intrauterine growth restriction, fetal acidemia,
and increased risk for both perinatal morbidity and mortality, particulariy due to the risk
of prematurity.58
1.3.6. Preeclampsia: Clïnical features
1.3.6.1. Riskfactors
A variety of risk factors for preeciampsia have been identified,259 such as nulliparity,
extremes of maternai age, family history of preeclampsia, history of preeciampsia in a
previous pregnancy, preexisting hypertension or renal disease, uric acid ievel, diabetes
mellitus, multiple gestation, hydatidiform mole and hydrops fetalis. Certain of these risk
factors could potentially be useful for identifying patients for prophylactic therapy, but
many patients develop the disease with no risk factors other than nulliparity.59
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1.3.6.2. Ciinicat manifestations ofpreeclampsia
Hypertension, edema and proteinuria remain the most important clinical hallmarks
of the condition.2 Blood pressure should be measured with the patient in the siffing
position after five minutes of rest.2 By convention, the blood pressure should be
documented to be abnormal on at Ïeast two separate occasions, four or more hours apart.
The loss of serum protein and the increase in capillary endothelial permeability lead
to a decrease in intravascular volume and increased tissue edema.6° Edema is not required
for the diagnosis ofpreeclampsia. Indeed, it is common in many healthy pregnant women:
edema of the face or hands is reported in 64% of normotensive women, whereas as many
as 40% of women with eclampsia have no edema before the onset of convulsions. While
it is difficuit to distinguish the harmless, physiologie edema of pregnancy from the edema
of preeclampsia, suspicion should be raised if pedal edema (1+ or greater) does flot
resolve with ovemight rest, in the presence of edema of the face and hands, and edema
associated with more than 2 kg ofweight gain in a week.261
Proteinuria is somewhat easier to define and interpret than edema. Excretion of
greater than 300 mg of protein per 24 hours is considered abnormal; this usually
correlates with reading of “1+” or greater by dipstick examination2 and is generally
associated with the classic pathological finding of glomeruloendotheliosis,62 which is flot
permanent but recovers after delivery. Detection of mild proteinuria on dipstick
examination (“1+” or greater) should prompt a 24-hour urine collection if there is clinical
suspicion of toxemia and if the resuits will alter clinical management. The detection of
heavy (“2+” or greater) proteinuria is alrnost always pathologic in the absence of urinary
tract infection or heavy vaginal contamination.2 The presence of proteinuria confirms the
diagnosis of preeclampsia and the concomitant increase in risk for both mother and
fetus.63 The risk is related simply to the presence of proteinuria; it is not affected by the
absolute value ofthe increase in urinary protein excretion.64
Several body systems are involved in the pathologic changes of preeclampsia. In the
central nervous system, cerebral edema is associated with convulsions and can be seen on
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computer tomography and magnetic resonance imaging. Cerebral edema may antedate
eclampsia, because occipital lobe blindness can occur in the absence of eciampsia and is
completely reversible. Certain signs and symptoms in the gastrointestinal, cardiovascular
and renal system are both common and nonspecific.
1.3.6.3. Laboratoiy abnorntatities in preectampsia
Many controversies exist concerning the use of laboratory testing for early diagnosis
of preeclampsia.
A decrease in blood volume can occur in preeciampsia, can lead to maternai
haemoconcentration and is associated with an increased risk of intrauterine growth
restriction.63
Several abnormalities of the coagulation system can occur in preeclampsia. These
include changes in piatelets, the coagulation cascade and in the fibrinolytic systems.
Their common pathophysiology is likely vascular endothelial damage or activation.
Studies of platelet function in preeclampsia suggest increased activation, decreased
numbers, and shorter lifespan.6566 In normal pregnancy, the platelet count can fali below
20x1 09/L because of the normai maternai blood-volume expansion. In preeclampsia, the
platelet count falis further and may be an indication of progressive disease.63 This fali is a
resuit of both increased consumption and intravascular destruction. Associated
coagulation abnormalities are likely if the count is below 100x109/L.67 A low platelet
count is one component ofthe HELLP syndrome (hemolysis, elevated liver enzymes, and
low platelets), which carnes a particular risk to the mother.68 Fay69 reported that declining
platelet counts were more significant than the absolute level.
Uric acid levels normally fail in pregnancy because renal excretion increases, so
comparing the pregnant patient’s uric acid with reference values for nonpregnant patients
may be falsely reassuring.269 Renal perfusion in preeclampsia is Iess than in normal
pregnant women, trending toward the degree of perfusion observed in the nonpregnant
state as the disease worsens. Uric acid excretion in preeclampsia is decreased
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predominately due to its enhanced tubular reabsorption and decreased renal clearance7°
resulting in a higher than normal plasma levels.7’ Plasma uric acid levels generally
correlate with severity of disease,72 and high level s have been associated with poor fetal
outcome.73 Roberts59 reported that the senim une acid concentration ‘is a particularly
sensitive marker of preeclampsia available to clinicians’. The mean une acid level of
normal pregnant women is 3.8 mg/dL (228 jimol/L), whereas it is 6.7 mg!dL (402
tmol/L) in preeclampsia, with levels reaching 9.0 mg/dL (540 imol/L) in severe
disease.74
Liver involvement in preeclampsia is variable but is the cause ofthe upper epigastric
pain commonly seen in the disorder. The liver swells as a resuit of local edema secondary
to inflammatory infiltrates and obstructed blood flow in the sinusoids. Haemorrhage can
occur beneath the liver capsule and may be so extensive as to cause rupture ofthe capsule
into the peritoneal cavity. If a haematoma or haemorrhage is suspected, the liver should
be examined by ultrasonography.75 Liver involvement can be assessed by measurement
of alanine aminotransferase and aspartate aminotransferase activities in serum: they
increase in preeclampsia as a result of leakage across celi membranes. Increases in these
enzymes are part of the HELLP syndrome.68 With substantial liver involvernent there are
coagulation abnormalities that resuit from hepatic dysfunction. Disseminated
intravascular coagulation is a rare complication of preeclampsia in the absence of
placental abruption.76
Renal function is generally maintained in preeclampsia until the late stage. In normal
pregnancy, there is an increase in creatinine clearance with a concomitant decrease in
serum creatinine and urea concentrations. If creatinine concentrations are high early in
the disease process, underlying renal disease should be suspected. In severe disease,
increases in serum creatinine can be seen and are associated with worsening outcome.77
Acute renal failure is now rare in preeclampsia in more developed countries;78 most cases
are associated with haemorrhage or sepsis. Most cases of renal failure are due to acute
tubular necrosis, and most patients recover with no long-term renal impairment.78 Acute
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cortical necrosis, a permanent cause ofrenal failure, occurs in iess than 4% of ail cases of
renal failure in preeciampsia.79
In recent years, generalized systernic inftamrnatory response lias been reported, of
which endothelial dysfunction is an important cornponent80. In 2004, Levine8 reported in
a nested case control study that excess circulating soluble fms-like tyrosine kinase 1 (sFit
1, also referred as sVEGFRI), an antiangiogenic protein, which released by hypoxic and
dysfunctionai placenta, binds placentai growth factor (PIGF) and vascular endotheliai
growth factor (VEGf), preventing th.eir interaction with endothelial receptors on the celi
surface and inducing endothelial dysfiinction, before clinical signs of preeclarnpsia
appeared. The levels of serum sFÏt-1 increased and PIGF decreased earlier and more
pronounced in the pregnant women who progressed to preeclampsia later than that of
normotensive wornen, whose levels of serum sFlt-l rnoderately elevated and PIGf
decreased during thc last two rnoths of pregnancy. In 2006, Levine82 also reported that
serum soluble endoglin, another antiangiogenic protein, increased markediy 2-3 months
carlier than clinical preeciarnpsia onset.
Table X summarizes the literature on iaboratory abnormaiities in relation to the
severity of preeclarnpsia.4183 The cut offs are only provided as reference guidelines for
research and clinical management.
1.3.6.4. MaternaI riskfactors forprogression front itoit-protebturic gestationat
hypertension to preectampsia
To a large extent, the etiology of preeclampsia remains poorly understood. During
the last fifteen years, many clinicai, biophysicai and biochemical tests have been
proposed for the identification of women who are at increased risk for developing
preeclampsia.81 -$6
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Some previous research provides insight into risk factors for preeclampsia and
gestational hypertension, and more specifically conceming risk factors for the
progression from gestational hypertension without proteinuria to preeclampsia.
In 1998, Ros87 reported type 1 diabetes (OR = 5.98), gestational diabetes (OR = 3.11)
and twin birth (OR = 4.17) as significant risk factors for preeclampsia, whereas the
associations between these variables and the risk of gestational hypertension were weaker
and nonsignificant. Obese women (Body mass index > 29) had an increased risk of both
gestational hypertension (OR = 4.85) and preeclampsia (OR 5.19).87 Some studies have
reported that uric acid levels are significantly elevated in women with gestational
hypertension and preeclarnpsia as compared to normotensive pregnant women.8889
Women who developed preeclampsia following gestational hypertension presented
earlier than those who remained with gestational hypertension until delivery. In a
retrospective study, prior miscarriage, serum albumin, high hematocrit, creatinine and
uric acid were associated with an increased likelihood of progression from gestational
hypertension to preeclampsia.9° It has been suggested that the serum uric acid
concentration is “the most sensitive indicator of preeclarnpsia available to clinicians.”59
Among women with gestational hypertension of pregnancy, the likelihood ratio of
developing preeclampsia with a serum uric acid value of 5.5 mg!dL (330 imo1/L) or
higherwas 1.41.88
The onset of abnormal uric acid clearance precedes any measurable decrease in the
glomerular filtration rate.91 In addition, histological studies performed on renal biopsy
specirnens suggest that hyperuricemia correlates with the presence of gomem1ar lesions
that characterize preeclampsia.92 Jncreased oxidative stress and formation of reactive
oxygen species have been proposed as another contributing source of the hyperuricemia
noted in preeclampsia.93 Furthermore, several investigators have documented a
correlation between hyperuricemia and both the severity of disease and neonatal
morbidity.9496 In fact, one study found serum uric acid concentration to be a better
predictor of low birth weight than blood pressure.97
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In summary, current reports about the risk factors for progression from gestational
hypertension to preeclampsia are few and resuits are inconsistent. Several factors, such as
gestational diabetes, twin birth, early gestational age at the onset of gestational
hypertension, prior miscarriage, high hematocrit, serum albumin, creatinine and uric acid
have been reported to be risk factors.
1$
2. Thesis project
2.1. Rationale and objectives for current study
Hypertensive disorders in pregnancy affect about 6 to 10 % of ail pregnancies and
remain a major cause of maternai and neonatal mortality and morbidity worldwide.
According to the classification recommended by the National High Blood Pressure
Education Program,’5 hypertension during pregnancy is categorized as follows:
preeclampsia (PE) / eclampsia, gestational hypertension (GH), the continued presence of
chronic hypertension, and the superimposition of preeclampsia on chronic hypertension.
These categories identify disorders with different epidemiological characteristics,
pathophysioiogy and risks for mother and baby.38
Gestational hypertension (GH) is usually defined as an elevated blood pressure (BP)
arising after 20 weeks of gestation in the absence of significant proteinuria, and is
generaliy characterized by more favourable maternai and fetai outcomes than is
preeclampsia.98 Wornan with gestational hypertension may progress to preeclampsia.
However, in many cases proteinuria neyer occurs, the course is relativeiy benign and
blood pressure normalizes afler delivery.
Preeclampsia (PE) is a complex multi-system disorder ofhuman pregnancy, with an
incidence of 2-5%. It is characterized by eievated BP occurs which aller 20 weeks of
gestation, accompanied by new-onset of significant proteinuria. Other maternai organ
dysfunctions may be associated, such as renal impairment, liver dysfunction or
abnormalities of coagulation (thrombocytopenia, disseminated intravascular
coagulation).299101 This is a far more serious disorder with potentiaiiy more severe
consequences for both mother and fetus, such as preterm delivery, fetal growth
retardation, and perinatal mortaiity.
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Hypertension is usually the first clinical feature of preeclampsia, before the onset of
proteinuria in most cases. At first presentation, it is oflen difficuit to know if a pregnant
woman with new hypertension will remain in that state or progress to preeclampsia. As
the outcomes of these disorders are different, it is mandatory to treat each case as
emerging preeclampsia. On the other hand, most women with gestational hypertension
may be managed safely as outpatients, and it would be helpful to know both the absolute
risk of progression from gestational hypertension to preeclampsia, and the factors at
initial presentation which predict this progression.
Up to now, the etiology of preeclampsia remains poorly understood. In recent years,
some clinical, biophysical, and biochemical tests have been suggested or reviewed to
identify women who are at increased risk for the development of preeclampsia,81838586
cspccially rising circulating levels of soluble frns-like tyrosine kinase 1 (sfltl) and ratios
of sFitl /PIGF (p]acentai growth factor) before the onset of preeciampsi a. However, some
of these tests are invasive, whereas others require expensive techniques or special
expertise that precludes their utility in routine screening. It is well recognized that
pregnant women with multiple fetuses, previous preeclampsialeclampsia, insulin
dependent diabetes, and previous poor pregnancy outcomes are at increased risk for
preeclampsia.’°2’103 In 2000, Odegard 104 reported in a population based, nested case
control study that women with preeclampsia in a previous pregnancy had a strongly
increased risk of severe preeclampsia and early onset disease. In a case control study,
matemal age above 26 years, multiparity, and no prenatal care were reported to be risk
factors for the development ofeclampsia.’°5
Study objectives: It remains unknown exactly what factors predict the progression
from gestational hypertension to preeclampsia. The objectives ofthis study were:
1) To explore differences in sociodemographic and obstetrical characteristics
between women with gestational hypertension who progressed to preeclampsia and those
who remained in the gestational hypertensive state until delivery.
2) Among women who presented with gestational hypertension, to assess individual
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predictors of progression to preeclampsia.
3) To create a multivariable prediction model for the progression from gestational
hypertension to preeclampsia based on commonly available prenatal clinical and lab
testing data and to assess the sensitivity, specificity, positive predictive value and
negative predictive value ofthis model.
The study variables were those that can be identified at their initial presentation with
gestational hypertension by the already available clinical andlor laboratory features. Such
a study may help to uncover important clinical features that could facilitate early
prediction of progression from gestational hypertension to preeclampsia, enhance the
effectiveness of care and minimize the risk of potentiaiiy serious maternai and neonatai
complications.
2.2. METHODS
2.2.1. Definitions
Gestationat hypertension is defined as the onset of hypertension (systolic BP 140
mrnHg andlor diastolic BP 90 mmHg) afier 20 weeks of gestation which returned to
normal within 3 months of delivery, without or with proteinuria of no greater than trace
levels. Hypertension in these women is confirmed afler either overnight rest in hospital or
following repeated BP measurements during the next few days visit.
Preeclampsia is defined as a systolic blood pressure (BP) 140 mrnHg andlor
diastolic BP 90 mrnHg with proteinuria 300 mg in a 24-hour urine collection or 1+ on
dipstick urinalysis in two samples taken 6 hours apart if 24 hour urine was unavailable.
Eclampsia is diagnosed when convulsions occur in a woman with preeclarnpsia.
Anthropometric parameters of the baby, such as birth weight, height and head
circumference were measured shortly afler delivery. Gestational age was based on the last
menstrnal period, and verified by first-trimester or early second-trimester ultrasound
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when available. If the date of the last menstrnal period was flot consistent with the resuit
of ultrasound examination, gestational age was based solely on the first-trimester or eariy
second-trimester ultrasound findings.
Small-for-gestational-age (SGA) was defined as birth weight below the 10th
percentile for gestational age according to the recently published Canadian sex-specific
fetal growth reference values based on infants bom in 199496.b06
2.2.2.Research design
This was a historicai prospective cohort study, based on maternai and perinatai
records of women who received obstetric care and delivered at Hôpital Sainte-Justine in
the period between March 2001 and June 2003 inclusive.
In this study, we firstly identified patients based on computerized obstetric delivery
records at the department of obstetrics and gynecoiogy. Thereafter, we ctsed these
patients’ personnel identification information to further access to the paper-forrnatted
medical chails, to extract the information of maternal sociodemographic, obstetrical and
clinical characteristies. Regarding to the detail items extracted from medical charts,
please refer to ANNEXES
— Information Extraction Form (page: xii).
Inclusion criteria: Women with a singleton pregnancy who were diagnosed as
having gestational hypertension without proteinuria at the initial presentation, either at
the time ofhospitalization or at an outpatient prenatal visit.
Exclusion criteria: Hypertensive patients were exciuded if they had
1) Multiple gestations, e.g. twins, triplets, quadrnplets
2) Chronic hypertension
3) Renal disease
4) Acute or chronic hepatitis
The medical charts of the women presenting with gestational hypertension were
reviewed to confirm whether they were eligible according to these criteria.
22
2.2.3.Clinical and laboratory data
Our study was approved by the hospital ethics review board. Data abstraction and
data cleaning were performed by Yuquan Wu and double checked by another research
student in the prenatai research unit of Hôpital Sainte-Justine.
The following clinical and laboratory data at initial presentation with gestationai
hypertension were obtained from the hospital records: maternai age, gravidity, parity,
smoking status, diabetes (gestational or pre-existing), prior spontaneous miscarriage
(obtained from patient history alone, therapeutic terminations excluded); prior preterm
birth, previous preeclarnpsia and gestationai hypertension history (multiparity only);
hemogiobin, hematocrit, platelet count, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), serum creatinine, uric acid (URA) and lactic acid
dehydrogenase (LDH). The laboratory data concerning other time-points (before GH
diagnosed, afier GH diagnosed but prior to admission for delivery, at admission, afier
admission prior to delivery, deiivery and after deiivery) were also collected when it was
recorded in the patient’s medicai chart.
Blood pressure (BP) and gestationai age (GA) concerning the foiiowing time points
were transcribed from the hospitai medical charts: when the diagnosis of gestationai
hypertension was first made, at the time of diagnosis of preeciampsia (if applicable), at
the time of admission to hospitai for delivery, at the time of deiivery and after delivery
during hospitaiization.
Other ciinical and iaboratory data include highest measured 24h proteinuria (mg/24h)
afler gestationai hypertension onset, number of days of hospitaiization during admission
for delivery, mode of the delivery, infant birth weight (g), height (cm), head
circumference (cm), placental abruption, fetai NICU admission and piacentai weight.
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In patients initially diagnosed as having gestational hypertension, clinical and
laboratory measures at first presentation of gestational hypertension were compared
between those who progressed to preeclampsia and those who remained with a diagnosis
of gestational hypertension until delivery.
Women were treated with various antihypertensives (catapres, labetalol, clonidine,
methyldopa, nifedipine, etc.) aiming to maintain systolic BP 110-140 mmHg and
diastolic BP 80-90 mmHg.
2.2.4.Dependent and independent variables
The primary dependent variable was progression from gestational hypertension to
preeclampsia. The factors that were potentially associated with this progression were
referred as independent or predictive variables. We assessed the sensitivity, specificity,
positive predictive value and negative predictive value ofthis model.
Independent variables were sociodemographic, obstetrical and laboratorial
characteristics of the patient at the time of initial presentation with gestational
hypertension. These included: gestational age at GH onset, maternai age, smoked,
number of prenatal visits, primigravidity, nulliparity, prior history of gestational
hypertension, prior history of preeclampsia, history of miscarriage, history of preterrn
birth or diabetes; also the following independent variables being measured at the initial
presentation with gestational hypertension: systolic and diastolic blood pressure,
hemoglobin, hematocrit, platelet count, liver enzymes (alanine aminotransferase,
aspartate aminotransferase), serum creatinine, uric acid, and lactic acid dehydrogenase
levels. Because of the information ofmother’s height missing in about 1/3 medical charts
(GH group: 32 cases, GH-PE group: 58 cases), body mass index (BMI) between the
groups was flot cornpared and not studied in multivariable Iogistic regression model.
We also conducted a descriptive analysis for certain clinical outcomes other than the
main outcome of interest, according to the present or absent of progression to
preeclampsia.
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As well, we documented gestational age at delivery, small for gestational age (SGA)
(according to the criteria of published Canadian fetal growth reference values based on
infants bom in 19949&06, birthweight below the tenth centile for gestational age), and
certain obstetrical and neonatal outcorne indicators.
2.2.5. Statistic analysis
Differences in continuous variables were tested by analysis of variance. Chi square
and Fisher exact tests were used for testing the difference between groups in categorical
variables.
Univariable logistic regression analysis was employed at first to evaluate individual
clinical and laboratory variables as potentially significant predictors for progression from
gestational hypertension to preeclampsia. Subsequently, multivariable logistic regression
analysis was employed to evaluate the effect of one variable controlling for other co
variables. We used the STEPWISE routine as the model selection rnethod. This algorithm
specifies 0.05 as the critical alpha level for entering a variable into the model and 0.10 as
the significance level for a variable to remain in the model.
For rnost continuous variables, because standard deviation (SD) was pretty large and
one crude unit of change (e.g. serum uric acid: 1 jimol/L) is clinically meaningless, we
used one standard deviation (SD: 56.1 jimol/L for serum uric acid) as the unit increase to
calculate its crude or adjusted odds ratio, 95% confidence interval and P-values.
The sensitivities and specificities of the variables which had significant associations
with the outcome (progression from gestational hypertension to preeclampsia) in a
multivariable logistic regression analysis were also explored. This was followed by the
development of a receiver-operator characteristic (ROC) curve to determine a suitable
cut-off value for creating a model which used dichotomous variables, and calculating the
model’s sensitivity, specfficity, positive predictive value (PPV) and negative predictive
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value (NPV), as well as the probability of progression to preeclampsia from gestational
hypertension under various possible common clinical combinations of these variables.
We calculated different predicted sensitivities and specificities under various cut-off
points ofprobabilities of progression from gestational hypertension to preeclampsia in the
multivariable logistic regression model and depicted the relevant ROC curve. The
exploratory analysis (Table VIII, Fig. 4) suggested that a cut-off value of the predicted
probability of 50% or 60% was associated with a good sensitivity and specificity (Fig. 4).
If a patient’s predicted probability of progression from gestational hypertension to
preeclampsia was more than 50% in the logistic predictive model, then this woman was
considered as having a positive test resuit (progressed to preeclampsia from gestational
hypertension) for calculating the sensitivity, specificity, positive predictive value and
negative predictive value ofthis logit model.
Statistical analysis was performed using SAS sofiware (version 9.0, SAS Institute,
Cary, NC).
2.3. RESULIS
Because of the small number of patients with HELLP syndrome (hemolysis,
elevated liver enzymes, and low platelet count, 14 cases) and eclampsia (2 cases), these
cases were combined with preeclampsia cases into a single group, hereafler referred to as
“preeclampsia” in this study.
In all, 298 women were identified as having gestational hypertension at initial
presentation and either progressed to preeclampsia or remained gestational hypertension
until delivery. Women with multiple pregnancies (14 cases) were excluded from the
analysis, mainly because this variable is a potentially confoundiiig variable known to be
associated with both preeclarnpsia or gestational hypertension and birth weight.
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0f these identified patients, medical records were available for further review in
99% of cases. Two records of patients with gestational hypertension were excluded as
there were insufficient data available for this study.
Pregnancies complicated by chronic hypertension and preeclampsia superimposed
on chronic hypertension were excluded. Patients with renal disease or other secondary
causes of hypertension were also excluded, 2 patients with hepatitis B were also excluded
from the later research analysis, mainly because their elevated liver enzymes influenced
the analysis of liver enzymes predictors (alanine aminotransferase, aspartate
aminotransferase) for progression from gestational hypertension to preeclampsia, leaving
a total of 280 patients in the study.
0f the 280 wornen with the initial diagnosis of gestational hypertension at the first
presentation, 189 (65%) went on to develop preeclampsia.
Table I summarizes comparisons of maternaI demographic and obstetric
characteristics between the gestational hypertension group and the preeclampsia group.
Systolic BP and diastolic BP at admission for delivery and delivery were higher in
women who progressed to preeclampsia (GH-PE group) than among those who remained
with a diagnosis of gestational hypertension until delivery (GH group). The proportion
with a prior history of preeclampsia was two times higher in GH-PE group than in the
GH group.
There were no significant differences between groups in maternal age, or
proportions who were primigravid, nulliparous, smoked, had a past histoiy of diabetes,
miscarriage, preterm birth or prior history of gestational hypertension.
The proportion undergoing cesarean delivery in GH-PE group was twice of that
observed in the GH group. The number of days of maternaI hospitalization was also
longer in the GH-PE group than in the GH group. The number of prenatal visits between
GH and GH-PE groups was similar.
Table II summarize the differences in maternal clinical characteristics at initial
presentation with gestational hypertension and neonatal outcomes between these two
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groups. Women who progressed from gestational hypertension to preeciampsia (GH-PE
group) presented earlier with gestational hypertension (32±4 wks vs 38±2 wks) and were
delivered earlier (35±4 wks vs 38±2 wks) with higher rates of fetal intrauterine growth
restriction (TUGR) (27% vs 14%) and lower neonatal anthropometric parameters (birth
weight, height and head circumference). Fetal NICU admission was more frequent in the
GH-PE group than those who remained gestational hypertension until deiivery (GH group)
(30%vs3%).
The level of une acid (TIRA) at presentation with gestational hypertension was
significantly higher (mean difference=3 1 jimoi/L) in the GH-PE group than in GH group,
whereas the leveis of hemoglobin, hematocnit, piatelet count, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), creatinine and lactic acid dehydrogenase (LDH)
which were measured at time point of gestational hypertension onset were not
significantly different between the GH-PE group and the GH group. There were no
significant differences in systolic or diastolic biood pressure at the initial presentation
with gestational hypertension between the GH-PE and GH groups (Table II).
Univariable logistic regression analysis showed that a pnior history of preeefampsia,
serum unic acid level and gestationai age at first presentation with gestational
hypertension were significantiy associated with the progression from gestational
hypertension to preeclampsia (Table III). Independent variables which had no significant
association with the progression to preeclampsia from gestational hypertension, included
maternai age, primigravidity, nulliparity, smoking status and pnior history of gestational
hypertension, diabetes, history of miscarniage and history of preterm birth, as weil as the
following variables measured at first presentation with gestational hypertension: systolic
and diastolic blood pressure, hemoglobin, hematocrit, platelet count, alanine
aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine and serum
lactic acid dehydrogenase (LDH).
In the multivariable logistic regression analysis, the parameters which were
significantly associated with progression from gestational hypertension to preeclampsia
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were prior preeclampsia history, uric acid level and gestational age at initial presentation
with gestational hypertension. Adjusted odds ratios ofthese variables were slightly higher
compared to the crude ORs in univariable logistic regression analysis (Table W). This
was especially true for prior history of preeclampsia, where the OR increased from 2.74
to 3.43 afier adjusting for other variables. As regards serum uric acid concentration
rneasured at first presentation with gestational hypertension, the odds ratio was 1.7$ if we
applied one standard deviation value ofuric acid as the unit increase (56.1 jimol/L) in the
model (Table IV).
The test properties of serum uric acid and gestational age at first presentation with
gestational hypertension were assessed by examining sensitivity and specificity values
over different cutoff values (Table V) and by graphing receiver-operator characteristic
(ROC) eurves, respectively (Fig. 1, Fig.2).
From Fig. 1, a break point on the ROC curves for a gestational age of 36 weeks
appears to be reasonably sensitive (8 1%) and specific (86%). We note from figure 2 that
serum uric acid could flot achieve more than 80% for either sensitivity or specificity. The
level of 300 iimol!L (5 6%, 64%, respectively) appears to be the best cut-off value to
distinguish women who progressed to preeclampsia from those who remained with a
diagnosis of gestational hypertension until delivery.
Table VI presents the resuits of the analysis of the Logit model, using the same
variables as in the previous model (Table W) but applying the observed eut-off values
suggested from Table V, Fig. 1 and Fig.2, to form another Logit model where ail the
variables in the model were dichotomous variables. We provided the relevant regression
coefficients, adjusted ORs, 95% confidence interval and p values for calculating the
different predicted probability (Table VII) when we applied various possible common
combinations ofthese dichotomous variables identified in Table VI. The adjusted ORs of
gestational age less than 36 weeks at gestational hypertension onset, past history of
preeclampsia and une acid level more than 300 umol!L measured at first presentation
with gestational hypertension for the progression from gestational hypertension to
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preeclampsia were 3.63, 3.21 and 2.66, respectively. The formula suggested by this
prediction model was:
P (probability for progression from gestational hypertension to preeclampsia) =
exp (-1.34 + 1.29 x GA_LT36 + 0.98 x URA_GE300 + 1.17 x PAPE)
ti + exp (-1.34 + 1.29 x GA_LT36 + 0.9$ x URA_GE300 + 1.17 X PAPE)]
Notes:
GALT36: gestational age at GH onset, <36 weeks = 1, 36 weeks = 0.
URAGE300: Uric acid level at GH onset, <300 tmol/L 0, 300 iimol/L = 1.
PAPE: Past history ofpreeclampsia, being coded as: Yes = 1, No = 0.
Example:
If a patient at first presentation with gestational hypertension had the following
characteristics: Gestational age < 36 weeks, une acid level > 300 imo1IL and a positive
history of preeclampsia in a previous pregnancy,
thenP=exp(-1.34+1.29x1+0.98x1+1.17x1)/[1+exp(-1.34+1.29x1+0.98x
1+1.17x1)],
- P=exp(2.10)/{1+exp(2.10)],
- P=89%
Therefore, this pregnant woman would be estimated to have 89% probability of
developing preeclampsia.
Different predicted probabilities for progression from gestational hypertension to
preeclampsia according to various possible combinations of dichotomous variables
identified in Table VI are listed in Table VII and plotted in Fig 3. For a pregnant woman
presenting with gestational hypertension at less than 36 weeks and had prior preeclampsia
history, but with serum uric acid level less than 300 umol/L, the probability ofdeveloping
to preeclampsia would be 75%; whereas the probability would be 72% if the pregnant
woman’s gestational age less than 36 weeks and uric acid level more than 300 umol/L at
first presentation with gestational hypertension, but without a past history of
preeclampsi a.
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Table VIII lists relevant sensitivities and specificities using various cut-off points of
probabilities of progression from gestational hypertension to preeclampsia. The
corresponding ROC curve was plotted in Figure 4. The 50% or 60% cut-off values of the
predicted probability in the model (Table VI) had reasonably good sensitivity and
specificity (50% eut-off points: sensitivity$1.5, specificity=84.6; 60% eut-off points:
sensitivity78%, specificity=86.7), and the 50% eut-off point ofthe predicted probability
seemed to be the best combination of sensitivity and specificity for prediction of
progression from gestational hypertension to preeclampsia. Table IX lists the validity
parameters of the model using the P = 0.50 as the eut-off point: sensitivity 8 1.5%;
specificity = 84.6%; agreement rate = 82.5%; positive predictive value (PPV) 91.7%
and negative predietive value (NPV) = 68.8%.
2.4. DISCUSSION
Until now, few studies had been reported on the topie of risk factors for the
progression from gestational hypertension to preeclarnpsia, especially the different
characteristies at the initial presentation with gestational hypertension for progression to
preeclampsia versus remained gestational hypertension until delivery. We have
established a model to prediet this progression with reasonably good sensitivity,
specificity, positive predictive value, and negative predictive value. We have explored the
differences in charaeteristics at the time point of gestational hypertension onset between
women who remained as gestational hypertension and those who progressed from
gestational hypertension to preeclampsia. Our study focused on clinical, obstetrical and
laboratory characteristies that are routinely available at the time of initial presentation
with gestational hypertension. The present study provides new data on strategies for the
identification of patients who will progress to preeclampsia from gestational hypertension.
Several studies’°5’°7”°8 examined risk factors for the development of eclampsia, but
these studies compared eclampsia either with preeclamptic controls or with non
preeclamptic controls, or with uncomplicated eclamptic controls (not complicated by
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intracerebral hemorrhage, pulrnonary edema, renal, hepatic, respiratory system
dysfunction or HELLP syndrome). We investigated specifically the risk factors for the
development of preeclampsia among patients whose initial presentation was gestational
hypertension. Hypertension is the most common first presentation of preeclampsia42 and
the recording of raised blood pressure together with urinalysis for proteinuria are the
major screening tests for detecting preeclampsia.
In epidemiologic studies, special attention should be paid to medical surveillance (or
detection) bias, which occurs when the identification of the outcome is flot independent
of the knowledge of the exposure. In our study, we found no difference in the number of
prenatal visits between patients who progressed from gestational hypertension to
preeclampsia and those who remained as gestational hypertension until delivery (Table I).
This suggests that medical surveillance between the preeclampsia group and the
gestational hypertension group was similar, and the number ofvisits was not a risk factor
for the progression from gestational hypertension to preeclampsia.
hi univariable logistic regression analysis, variables such as gestational age at first
presentation with gestational hypertension, previous preeclampsia and serum uric acid at
initial presentation with gestational hypertension were significant risk factors for
progression to preeclampsia from gestational hypertension (Table III). Multivariable
logistic regression analysis confirmed these variables were influential matemal risk
factors for the development of preeclampsia from gestational hypertension. Adjusted
odds ratios of these variables were slightly higher than the cnide ORs in univariable
logistic regression analysis, especially for the past history of preeclampsia (adjusted OR
= 3.43, cntde OR = 2.74), suggesting that a past history of preeclampsia is an important
risk factor in the progression from gestational hypertension to preeclampsia (Table W).
Some studies reported that women who had preeclampsia in a first pregnancy have
5-8 times the risk of preeclampsia as that in a second pregnancy.49’°9’12 Our study
indicated that women with gestational hypertension who had prior history of
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preeclampsia have a 3 to 4-fold risk of progression to preeclampsia than those without a
history ofpreeclampsia (Table W).
It has been suggested that the serum uric acid level is “the most sensitive indicator of
preeclampsia available to clinicians.”59 Plouin et al. 113 documented poor perinatal
outcomes (including stillbirths and neonatal deaths) in pregnancies complicated by
preeclampsia and elevated serum uric acid levels. In their study, 59% of women had
serum une acid levels 360 mol/L in the group with poor perinatal outcomes compared
to 20.3% in the group with favorable perinatal outcomes. Siemons and Bogert’14 were the
first to report an association between semm uric acid concentration and preeclampsia in
1917. Later in 1934, Stander et al”5 first reported the correlation between serum une acid
level and severity of preeclampsia. Histological evidence from biopsy”6 reveals frequent
renal involvement in cases of preeclampsialeclampsia. Tubular function is the first to 5e
involved and later in the disease process glomerular function is impaired. Uric acid is
used as an indicator of disease severity in established preeclampsia and has been reported
to be a better predictor for adverse perinatal outcome than blood pressure.83 However, we
did flot find it to be an important factor for the severity of preeclampsia. h most patients,
the increase in unie acid level seems to coincide with the increase in blood pressure, and
precedes development of the proteinuric stage which is a sign of glomerular damage of
the disease.”7 Uric acid concentrations have been used for early detection of
preeclampsia, but not for hypertension”7 However, the reported low sensitivity and
specificity in most studies renders uric acid measurement unhelpful for widespread use of
early detection of preeclampsia.”8
Our data suggest that serum unie acid levels measured at initial presentation with
gestational hypertension were significantly higher in women who developed
preeclampsia than those who remained as gestational hypertension until delivery,
although mean serum uric acid levels in these 2 groups were in the normal reference
range (< 350 iimol/L). Serum uric acid levels were also significantly associated with
progression from gestational hypertension to preeclampsia in a multivariable logistic
regression analysis (Table W). The odds of developing preeclampsia from gestational
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hypertension increased by 78% for each standard deviation (56.1 jimol/L) increase in
serum uric acid level measured at gestational hypertension onset. The cutoff value of 300
.tmol/L is only moderately sensitive (56%) and specific (64%) (Table V, fig 2) for
predicting the development of preeclampsia from gestational hypertension, similar to
those reported by Lim, KH88. Redman et al.”9 showed that serum une acid levels 420
jimol/L were associated with significant perinatal mortality and matemal morbidity and
were of great value when the diagnosis of preeclampsia was in doubt. Koike’2° also
reported that the elevation of serum une acid levels occurs earlier in twin gestations than
in singletons and may serve as a useful early predictor of the development of
preeclampsia.
There were significant differences in gestational age at initial presentation with
gestational hypertension between those who developed preeclampsia from gestational
hypertension and those who remained with gestational hypertension until delivery, the
GH-PE group presenting significantly earlier than GH group (32±4 vs 38±2 weeks)
(Table II). The optimal cutoff value for predicting preeclampsia progression from
gestational hypertension was 36 weeks of gestational age at first presentation with
gestational hypertension. Sensitivity and specificity were 81% and 86% (Table V, Fig 1),
respectively. Women who are diagnosed earlier with gestational hypertension are more
likely to develop preeclampsia.
The adjusted odds ratio for gestational age less than 36 weeks at gestational
hypertension onset was highest among the variables in the model (aOR 3.63) (Table
VI), indicating this risk factor had the strongest association with the progression from
gestational hypertension to preeclampsia. A prior history of preeclampsia was the second
variable in importance on this progression (aOR 3.2 1) (Table VI). If a pregnant woman
who had a history of preeclampsia and presented gestational hypertension earlier than 36
weeks in the current pregnancy, she would have a very high probability to develop
preeclampsia. Limited information is available regarding the risk of progression to
preeclampsia from gestational hypertension according to gestational age at disease onset.
Barton’2’ in a prospective cohort study reported that among patients with a singleton
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pregnancy between 24 and 35 week’s gestation accompanied with mild gestational
hypertension, nearly 50% ultimately developed preeclampsia and 10% progressed to
severe disease, indicating early onset of mild gestational hypertension was associated
with the progression to preeclampsia. This was also confirmed by Sanchez-Ramos122 who
reported that approximately 50% of women with mild preeclampsia remote from term
(24-36 weeks) would develop severe preeclampsia.
The parameters of validity of our multivariable prediction mode! (sensitivity: 81.5%,
Specificity: 84.6%, positive predictive value (PPV): 91.7%; negative predictive value
(NPV): 68.8%) suggested it was likely a good model for predicting the progression to
preeclampsia from gestational hypertension. It is clear from Table VIII and Figure 4 that,
for this multivariable prediction mode! (Table VI), the predicted probability: 0.50 or 0.60
seemed to be a good cut-off value with respect to both sensitivity and specificity for
predicting progression from gestational hypertension to preeclampsia. As preeclampsia is
a disease with important clinical implications, we gave priority to sensitivity in selecting
the cut-off value for the mode!.
b our knowledge, this is the first study designed to predict the progression from
gestational hypertension to preeclampsia. Braun123 in 1997 reported in a case control
study that uric acid (URA), !ow density lipoproteins (LDL), phosphoglycerate kinase
(PGK), mean platelet volume (MPV) and decreases in glyceraldehyde phosphate
dehydrogenase (G3PD) were associated with preeclampsia compared with non
hypertensive pregnancies, and creating the following predictive model: Probability to
develop preeclampsia = 0.7764 (URA) + 0.8086 (PGK) -0.7032 (G3PD) + 0.1399 (LDL)
-0.2386 (MPV). However, their study is a comparison of preec!ampsia versus healthy
pregnant controls.
In our study, potential se!ection bias (Berksonian bias) must be acknow!edged.
Selection bias occurs when a systematic error emerges in the ascertainment of study
subjects. Preeclampsia patients, especially severe preeclampsia patients, were often
referred to our hospital for treatment, delivery and were therefore available for chart
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review in our study. Some patients who presented with mild preeclampsia or gestational
hypertension may be managed and delivered in other hospitals, and their profile may
differ from patients included in our study.
We have developed a multivariable prediction model with reasonably good validity
parameters for predicting the progression from gestational hypertension to preeclampsia,
based on common clinical and laboratory test resuits available in routine prenatal care.
The model may be useful to the clinicians to stratify gestational hypertensive women’s
risk level according to their gestational age and une acid level at first presentation with
gestationaÏ hypertension, as well as whether there was a prior history of preeclampsia.
For example, woman with onset of hypertension afler 36 weeks of gestation, without
other features of preeclampsia, has only a small risk of developing preeclampsia and can
be managed safely as an outpatient.
Clinical monitoring of these risk factors in pregnancies complicated by gestational
hypertension could provide an easy, inexpensive and helpful tool for identifying women
with gestational hypertension at high risk of developing preeclampsia, therefore directing
tertiary perinatal care to reduce the incidence of adverse perinatal outcomes. Sorne other
potential risk factors for predicting the progression to precclarnpsia, such as body mass
index, sfit-1, PIGF, VEGF and serum soluble endoglin, should be included in th.e study,
as well as studied in the multivariable logistic regression model, to make the model more
stabi.lized and vaiid. This study provides new method to investigate the progression to
preeclampsia; further larger scale prospective studies which include more risk factors arc
warranted to test the efficacy of this model in predicting the progression to preeclampsia
from gestational hypertension.
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LI$T 0F TABLES
Table I. Comparison of maternai sociodemographic and obstetrical characteristics
between patients with gestatioiwt hypertension (GH) and preeclampsia (GH-PE,
progressed from gestationai hypertension to preeclampsia)
.
. GH GH-PEMaternai information (N 91) (N=]89)
Maternai age (years) 30 ± 5 30 ± 6
Prirnigravidity (%) 48 40
Nulliparous (%) 68 63
Smoking (%) 12 11
Past history of diabetes (%) 3 4
Past history ofrniscarriage (%) 35 40
Past history of preterm birth (%) 17 20
Past history ofpreeclampsia (%) 17 38*
Past history of gestational hypertension (%) 38 52
Number ofprenatal visits 8.5 ± 2 8.3 ± 2
Systolic BP at admission for delivery (mniHg) 145 ± 10 152 + 15**
Diastolic BP at admission for delivery (mmHg) 86 ± 8 91 ± 10
Systolic BP at delivery (mmHg) 142 ± 14 151 ± 15
Diastolic BP at delivery (mmHg) 81 ±10 88 ±1 1 **
Placental Abrnption (%) 0 6*
Mode ofdelivery: Cesarean (%) 21 42**
Gestational age at preeclampsia onset (weeks)
- 34 ± 4
Gestationai age at delivery (weeks) 38 ± 2 35 ± 4**
Days ofhospitalization 4 ± 2 7 ± 5**
GH group: Gestational Hypertension
GH-PE group: Progression from gestational hypertension to preeclampsia
* Significant P <0.05, * * Significant P <0.01. Mu1tiparae only.
Values are given as Mean ± SD for continuous data.
B?: blood pressure
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Table II. Comparison of maternai clinical characteristics at patients with gestationai
hypertension onset and neonatai outcomes between gestatio,:at hypertension (GH) and
preectampsia (GH-PE, progressed from gestationai hypertension)
Piacental weight (g)
GH group: Gestationai Hypertension
Gil-PE group: Progression from gestationai hypertension to preeclampsia
490±100 430±148**
* Significant P < 0.05, * * Significant P < 0.01. Multiparae only.
Values are given as Mean ± SD for continuous data.
GH: gestational hypertension; BP: blood pressure; ALT: alanine aminotransferase; AST: aspartate
aminotransferase; LDH: lactic acid dehydrogenase; SGA: small for gestational age, birth weight
below the 10t1 percentile for gestational age.
Clinical & lab data at Gil presentation Gil
Gestationai age at GH onset (weeks) 38 ± 2 32 ± 4**
Systolic BP at GH onset (mmHg) 147 ± 9 146 ± 9
Diastolic BP at GH onset (mmHg) 87 ± 8 86 ± 9
HemogiobinatGHonset(g/dL) 122±13 121 ± 11
Hematocrit at GH onset (%) 0.36 ± 0.03 0.36 ± 0.04
Piatelet count at GH onset (109/L) 215 ± 69 211 ± 51
ALT at GH onset (U/L) 16 ± 5 18 ± 6
AST at GH onset (U/L) 24 ± 6 24 ± 6
Creatinine at GH onset (moi/L) 58 ± 12 59 ± 1 1
Une acid at GH onset (imoi/L) 271 ± 61 302 ± 50**
LDHatGHonset(U/L) 152±23 149±24
Neonatal outcome
SGA(%) 14 27*
Birthweight(g) 3277± 642 2409±957**
Infant height (cm) 51 ± 4 47 ± 5
Infant head circumference (cm) 34 ± 2 32 ± 3**
NICU admission (%) 3 30**
J
j
T
ab
le
II
I.
Fa
ct
or
s
as
so
ci
at
ed
w
ith
pr
og
re
ss
io
n
fro
m
ge
st
at
io
n a
lh
yp
er
te
ns
io
n
to
pr
ee
ct
am
ps
ia
(U
niv
ari
ab
le
lo
gi
st
ic
re
gr
es
si
on
an
al
ys
is)
Pr
ed
ic
to
r
C
ru
de
O
dd
s
ra
tio
95
%
c
o
n
fid
en
ce
in
te
rv
al
P
v
a
lu
e
G
es
ta
tio
na
l a
ge
at
G
H
o
n
se
t
(w
ee
ks
)
0.
52
0.
45
—
0.
62
<
0.
00
0 1
U
ne
ac
id
le
ve
la
t
G
H
o
n
se
t
(im
o1
JL
)
1.
7$
1.
36
2.
32
<
0.
00
01
Pa
st
hi
st
or
y
o
fp
re
ec
la
m
ps
ia
2.
74
1.
02
—
7.
40
0.
04
62
Pa
st
hi
sto
ry
o
fg
es
ta
tio
na
ih
yp
er
te
ns
io
n
1.
55
0.
76
3.
14
0.
22
55
M
at
er
na
i a
ge
(ye
ars
)
1.
02
0.
98
—
1.
07
0.
38
42
Sy
sto
lic
BP
at
G
H
o
n
se
t
(m
mH
g)
0.
84
0.
65
—
1.
07
0.
15
03
D
ia
st
ol
ic
BP
at
G
H
o
n
se
t
(m
mH
g)
0.
22
0.
64
—
1.
06
0.
12
39
H
em
og
lo
bi
n
at
G
H
o
n
se
t
(g/
dL
)
0.
8$
0.
69
1.
14
0.
33
53
H
em
at
oc
ri
ta
tG
H
on
se
t
0.
92
0.
72
1.
18
0.
51
16
Pl
at
el
et
co
u
n
t
at
G
H
o
n
se
t
0.
94
0.
74
—
1.2
1
0.
63
73
A
LT
at
G
H
o
n
se
t
(U
/L
)
1.
25
0.
96
—
1.
64
0.
10
47
A
ST
at
G
llo
ns
et
(U
/L
)
1.
17
0.
90
—
1.
53
0.
23
64
00
DT
ab
le
II
I.
(C
on
tin
ue
d)
D
P
as
th
is
to
ry
of
pr
et
er
m
bi
rt
h
1.
13
0.
42
—
3.
05
G
H
:g
es
ta
tio
na
lh
yp
er
ten
sio
n;
BP
:b
lo
od
pr
es
su
re
;A
LT
:a
lan
in
e
ar
ni
no
tra
ns
fe
ra
se
;
A
ST
:a
sp
ar
ta
te
am
in
ot
ra
ns
fe
ra
se
;L
D
H
:l
ac
tic
ac
id
de
hy
dr
og
en
as
e
N
ot
e:
In
th
e
u
n
iv
ar
ia
bl
e
lo
gi
sti
c
re
gr
es
sio
n
an
al
ys
is,
th
e
ef
fe
ct
es
tim
at
es
ar
e
fo
r p
er
o
n
e
st
an
da
rd
de
vi
at
io
n
in
cr
ea
se
fo
rt
he
fo
llo
w
in
g
in
de
pe
nd
en
tc
o
n
tin
uo
us
v
ar
ia
bl
es
w
ho
se
v
al
ue
s
m
ea
su
re
d
at
th
e
in
iti
al
pr
es
en
ta
tio
n
w
ith
ge
sta
tio
na
lh
yp
er
te
ns
io
n:
U
ne
ac
id
(56
.1
jim
ol/
L)
;
Sy
sto
lic
BP
(8.
6m
m
H
g);
D
ia
sto
lic
BP
(8.
6m
m
H
g);
H
em
at
oc
rit
(0.
03
6 %
);
Pl
at
el
et
co
u
n
t(
57
.5
x
10
9/L
);
A
LT
(6.
0U
/L
);
Cr
ea
tin
in
e
(11
.4
p.
m
ol
/L
);
LD
H
(23
.8
U
IL
)
Pr
ed
ic
to
r
C
ru
de
O
dd
s
ra
tio
95
%
c
o
n
fid
en
ce
in
te
rv
al
P
v
a
lu
e
C
re
at
in
in
e
at
G
H
o
n
se
t
(tm
o1
JL
)
1.
10
0.
85
1.4
1
0.
47
18
L
D
H
at
G
H
on
se
t(U
/L
)
0.
89
0.
69
—
1.
14
0.
34
55
Pr
im
ig
ra
vi
di
ty
0.
70
0.
43
—
1.
16
0.
17
01
N
ul
lip
ar
ou
s
0.
81
0.
48
—
1.
38
0.
44
62
Sm
ok
in
g
0.
91
0.
42
—
1.
9$
0.
80
99
Pa
st
hi
st
or
yo
fd
ia
be
te
s
1.
30
0.
34
—
5.
01
0.
70
64
Pa
st
hi
st
or
yo
fm
is
ca
rr
ia
ge
1.
24
0.
74
—
2.
0$
0.
41
68
0.
80
45
H
em
og
lo
bi
n
(11
.6
g/
dL
);
A
ST
(6.
0U
/L
);
)
D
D
T
ab
le
IV
.F
ac
to
rs
si
gn
ifi
ca
nt
ly
as
so
ci
at
ed
w
ith
pr
og
re
ss
io
n
fro
m
g
e
st
a
ti
o
n
a
lh
y
p
e
rt
e
n
si
o
n
to
p
re
e
c
ta
n
ip
si
a
(M
ult
iva
ria
ble
lo
gi
sti
c
re
gr
es
si
on
an
al
ys
is,
v
ar
ia
bl
es
se
le
ct
io
n
m
et
ho
d
in
th
e
m
o
de
l:
St
ep
w
ise
)
Pr
ed
îc
to
r
A
dju
ste
d
O
dd
s
ra
tio
95
%
c
o
n
fid
en
ce
in
te
rv
al
P
v
a
lu
e
G
es
ta
tio
na
l a
ge
at
G
H
o
n
se
t
(w
ee
ks
)
0.
53
0.
44
—
0.
62
<
0.
00
0
1
Pa
st
hi
st
or
yo
fp
re
ec
la
m
ps
ia
3.
43
1.
02
11
.6
0
0.
04
71
U
ric
ac
id
le
ve
l a
t
G
H
o
n
se
t
(tm
ol
/L
)
1.
78
1.
26
2.
51
0.
00
11
GH
: g
es
tat
io
na
l h
yp
er
ten
sio
n
N
ot
e:
In
th
e
m
u
lti
va
ria
bl
e
lo
gi
sti
c
re
gr
es
si
on
an
al
ys
is,
u
n
it
o
fc
ha
ng
e
fo
rg
es
ta
tio
na
la
ge
at
G
H
o
n
se
t:
1w
ee
k
Pa
st
hi
st
or
y
o
fP
E
v
a
s
co
de
d
as
:
1=
Y
es
,0
=N
o
U
ni
to
fc
ha
ng
e
fo
ru
ric
ac
id
le
ve
la
t
G
H
o
n
se
t:
o
n
e
st
an
da
rd
de
vi
at
io
n
(56
.1
jim
ol/
L).
41
Table V. Sensitivity and specificity for various gestational age and serum uric acid cut
off values at GH presentation for predicting progression from gestatioizat hypertension to
preectarnpsia
Parameter Cutoff value Sensitivity (%) Specfflcity (%)
Gestational age at GH 30 30 99
presentation (weeks) 32 44 99
34 60 97
36 81 86
38 94 59
39 98 38
Uric acid at GH 220 92 25
presentation (tmo1/L) 240 88 36
260 83 45
280 74 59
300 56 64
320 39 73
340 29 84
360 19 93
GH: gestational hypertension
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ANNEXES
Information Extraction Form
xiii
Identification code
Rïsk factors for the progression from GH to PE
HÔPITAL SAINTE-JUSTINE
Le centre hospitallerUniversitaîre mère-enfant
Investigators: Yuquan Wu
William D Fraser, MD
Zhong-Cheng Luo, Phd, MD
n
Diagnosis:
Match 1, 2001 June 2003
The number of medical charts:
(Numéro du dossier hospitalier de la mère)
Baby Hospital Number:
(Numéro du dossier hospitalier du bébé)
The date of Medical chart review:
I—I—I—I—I—I......——I—I
I—I—I—I—I—I—I—I
I_I_I_I_I ‘ I_I_I I I_I_I
n
Information Extraction Form
xiv
Identification code III
Rïsk factors for the progression from GH to PE
I. General Information
1. Reasons de l’admission:
Complications de grossesse:
Travail:
Indication d’induction:
______________________________________________
Méthodes d’induction:
2. Date of Birth: I_I_I_[J (yyyy/mm/dd)
(Date de naissance)
3. MaternaI age: (years)
(Âge)
4. Blood pressure prior to pregnancy BP: mmHg
Date: I I I_I_I (yylmmldd)
5. Mother’s pre-pregnancy weight: I_I_IKg or Ibs
6. Mother’s height: cm or feet, inches
7. D.D.M: I__I (yy/mm/dd) D.P.A: I_I_I / I_I_Iii_I_I
(yylmmldd)
8. Date of admission for the delivery:
I_I_II I_L] I I_I_I _:__ GA: weeks days
(yy/mm/dd)
9. Date of the delivery:
/ I_I_I/I_I_I : GA: weeks days
(yy/mm/dd)
10. The GA of the delivery was determined by:
LMPI_I, ultrasound
_,
bothl_I
11. Gravidity: Parity:
xv
Identification code
Risk factors for the progression from GH to PE
Yes No Not indicated
12. Smoking during pregnancy E E E
If Yes, Detail
13. Alcohol (during pregnancy) E E E
If Yes, Detail
14. Drug dependent (Cocaine, Héroine, Marijuana, Autres)
E E
If Yes, Detail
15. Marital status: Married E Conjoint de fait E
Unmarried I Divorced / Separat E Other E Specify:
II. Previous medical hïstory
16. In the past history, whether there were following outcomes
1). In the past medical history
Yes No Not indicated
• Diabetes mellitus E E E
- IDDM (Type I) E E E
- NIDDM (Type II) E E E
• Chronic renal diseases E E E
• Other disease:
2). In the past pregnant history
Yes No Not indicated
• Multiple pregnancy E Number: E E
• Abortions E Number: I_I E E
(therapeutic terminations excluded)
• Preterm birth E Number: I_j E E
• Stillbirth E Number: I_j E E
xvi
Identification code
Risk factors for the proqressïon from GH to PE
• Preeclampsia E GA: E E
• Gestational hypertension E GA: E E
• GD fGestational Diabetes) E GA: E E
• Other medical disorder E E E
Diagnosis
III. Current Pregnancy
17. Prenatal visits:
1). The date of the first visit I I (yylmmldd)
Or gestational age (GA) wks days
2). The num ber of prenatal visits
Total: I_I_I
18
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Identification code
Risk factors for the progression from GH to PE
19. During the admission, whether there were Yes No
- GH (Gestational Hypertension) E E
- PE (Preeclampsia) E E
- Eclampsia E E
-Acuterenalfailure E E
- HELLP syndrome E E
- Others E E Specify:
20. The earliest GA when the diagnosis was made for OH (Gestational Hypertension)
GA: wks days Date: I_I_III_I_III_I_I
(yy/mm/dd)
21. The earliest GA when the diagnosis was made for PE (Preeclampsia)
GA: wks I_I days Date: I_I_I I I_I_I/i_I_I
(yy/mm/dd)
22. During the pregnancy, the hïghest proteinuria of 24h urine collection:
mg protein. GA: wks days
23. Therapy at hospital stay: Yes No
- Magnesium sulfate E E
- Antihypertensive medications E E
- Corticosteroïds E E
- Antibiotics
- Others E
24. Multiple pregnancy:
Single pregnancy Twin pregnancy Multiple pregnancy 3
xix
Identification code
Risk factors for the progression from GH to PE
25. Mode of the delivery Yes No
Cesarean delivery LI LI
(a). mother indications LI LI
(b). fetal indications LI LI
Vaginal spontaneous LI LI
Vaginal assisted LI LI
26. Whether there were following maternai and fetal outcomes or information
Yes No
1). Maternai information:
• Gestational diabetes LI LI GA:
• Premature rupture of membranes (37 wks) LI LI GA:
• Labor induction LI LI GA:
• Renal dysfunction : Oliguria LI LI Detail:
(<0.5 mllkg/h or < 500 m1124h)
• Blood loss during delivery LI LI Volume:
(>500 ml)
• Blood transfusion LI LI
• Antenatal inpatient days days
• Days hospitalized (mother) days
Yes No
2). Fetal information:
o Placental abruption LI LI GA:
o NICU admission LI LI
o Other complications LI LI Specify:
o Infant death (Stillbirth) LI LI
xx
Identification code
Risk factors for the progression from GH to PE
IV. Infantile Information
27. General information of the infant
+ Sex: Male Female
•• Birth weight I_I_I_I_I grams
+ Gestational age weeks days
+ Baby’s height I_I cm or inches
+ Head circumference of the infant: I_I_I. cm or inches
+ APGAR score: 1 min 5 min 10 min
+ Placental weight grams
+ Days hospitalized (infant) I_I_I days
28. Infant status Yes No
- Live birth
- Stillbirth D GA:
- Neonatal death El E] Days:
